Fate Therapeutics Inc
Research Fate Therapeutics Inc (FATE) on Bullrun: market cap USD 282.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFATE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 282.07M
- Financial periodFY2025
- RevenueUSD 6.65M
- Revenue growth-51.2%
- Net income-USD 136.32M
- Free cash flow-USD 112.04M
Valuation Snapshot
latest market cap is USD 282.07M.
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Frequently asked questions
What is Fate Therapeutics Inc's market cap?
Fate Therapeutics Inc's market capitalization is USD 282.07M.
What does Fate Therapeutics Inc do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.